Open access · OA
via OpenAlex
Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration
Simone Thomas, Remi Ben-Davies, Aysel Cetinkaya‐Fisgin, Xindan Hu, Xiaoling Li, Sarah Stewart, Baohan Pan, Jeffery L. Twiss, Rajiv R. Ratan, Dianna E. Willis, Michael J. Polydefkis, Ahmet Höke
Journal of the Peripheral Nervous System · 2026
Abstract
ABSTRACT Background and Aims Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD + ) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD + levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine‐nucleoside form of vitamin B3 and is an NAD + precursor. Methods To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo‐controlled, double‐blinded Phase 2 study. Results NR supplementation did not result in elevation of plasma NAD + levels but resulted in a small increase in NAD + in the skin samples. NR supplementation did not prevent capsaicin‐induced degeneration of the epidermal sensory nerve fibers, and there was no difference in the amount of epidermal reinnervation at the 90‐day visit. Although there was a small but statistically significant increase in the number of epidermal sensory nerve fibers at the 60‐day visit, these results are preliminary and will need to be validated in larger studies. Interpretation At present oral NR supplementation, at the doses used in this study, cannot be recommended to prevent neuropathy or to improve nerve regeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/jns.70101
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Thomas, S., Ben-Davies, R., Cetinkaya‐Fisgin, A., Hu, X., Li, X., Stewart, S., Pan, B., Twiss, J.L., Ratan, R.R., Willis, D.E., Polydefkis, M.J., & Höke, A. (2026). Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. <em>Journal of the Peripheral Nervous System</em>. https://doi.org/10.1111/jns.70101
Vancouver
Thomas S, Ben-Davies R, Cetinkaya‐Fisgin A, Hu X, Li X, Stewart S, et al. Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. Journal of the Peripheral Nervous System. 2026. doi:10.1111/jns.70101.
BibTeX
@article{simone2026Evalua,
title = {Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration},
author = {Simone Thomas and Remi Ben-Davies and Aysel Cetinkaya‐Fisgin and Xindan Hu and Xiaoling Li and Sarah Stewart and Baohan Pan and Jeffery L. Twiss and Rajiv R. Ratan and Dianna E. Willis and Michael J. Polydefkis and Ahmet Höke},
journal = {Journal of the Peripheral Nervous System},
year = {2026},
doi = {10.1111/jns.70101},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
iScience 2023
Open access · CC-BY
Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson’s disease
Journal of bioenergetics and biomembranes 2026
Citation only
Revitalizing aging muscles: harnessing NAD⁺, sirtuins, and exercise to combat sarcopenia.
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · CC-BY
Oral supplementation with Nicotinamide Riboside treatment protects RGCs in DBA/2J mouse model
Nutrients 2023
Open access · CC-BY
Defining NAD(P)(H) Catabolism
Nature Metabolism 2026
Open access · CC-BY
The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans
Scientific Reports 2016
Open access · CC-BY